Recent blog posts
NCT07616128 EVO-756 Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616128 EVO-756 Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616128 clinical trial report covering EVO-756, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616362 Albumin-Bound Paclitaxel Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616362 Albumin-Bound Paclitaxel Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616362 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07617818 Paclitaxel Cervical Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07617818 Paclitaxel Cervical Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07617818 clinical trial report covering Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616336 Chidamide Myelodysplastic Syndromes Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616336 Chidamide Myelodysplastic Syndromes Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616336 clinical trial report covering Chidamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616154 Abatacept Sickle Cell Trait Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616154 Abatacept Sickle Cell Trait Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616154 clinical trial report covering Abatacept, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07619066 Fulvestrant HER2 Mutation Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07619066 Fulvestrant HER2 Mutation Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07619066 clinical trial report covering Fulvestrant, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616206 Cadisegliatin Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616206 Cadisegliatin Diabetes Mellitus, Type 1 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616206 clinical trial report covering Cadisegliatin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07616882 Bupivacaine Anesthesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07616882 Bupivacaine Anesthesia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07616882 clinical trial report covering Bupivacaine, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261952 HS-20118 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261952 HS-20118 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
CTR20261952 clinical trial report covering HS-20118, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ChiCTR2600126018 Tagitanlimab PD-L1 positive Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ChiCTR2600126018 Tagitanlimab PD-L1 positive Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
ChiCTR2600126018 clinical trial report covering Tagitanlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07621406 Lenalidomide Diffuse large B-cell lymphoma recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07621406 Lenalidomide Diffuse large B-cell lymphoma recurrent Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07621406 clinical trial report covering Lenalidomide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07621497 Cetuximab Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07621497 Cetuximab Metastatic Colorectal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
23 July 2026
NCT07621497 clinical trial report covering Cetuximab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →